T. Rowe Price Associates
FHTX icon

T. Rowe Price Associates’s Foghorn Therapeutics FHTX Stock Holding History

T. Rowe Price Associates’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
24,478
+8,070
+49% +$44.3K ﹤0.01% 2961
2025
Q4 		$89K Hold
16,408
– – ﹤0.01% 2964
2025
Q3 		$81K Buy
16,408
+2,161
+15% +$11.5K ﹤0.01% 2960
2025
Q2 		$67K Buy
+14,247
New +$59.5K ﹤0.01% 2962

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

T. Rowe Price Associates's FHTX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Foghorn Therapeutics (FHTX) stake by 49% in Q1 2026, buying an estimated $44.3K and bringing the position to 24,478 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #2961.

T. Rowe Price Associates first reported a position in FHTX in Q2 2025 and has held it in 4 quarters since. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • T. Rowe Price Associates held 24,478 shares of Foghorn Therapeutics worth $118K as of Q1 2026.
  • T. Rowe Price Associates bought 8,070 Foghorn Therapeutics shares in Q1 2026, an estimated $44.3K.
  • Foghorn Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2961 holding.
  • T. Rowe Price Associates first reported a position in Foghorn Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.